3 ms·
If patents were a significant factor in the high prices for insulin in the USA, you would expect prices to be similarly high in all countries that recognize tho
by Someone 5y ago
If patents were a significant factor in the high prices for insulin in the USA, you would expect prices to be similarly high in all countries that recognize those patents.
They aren’t. https://www.rand.org/pubs/research_reports/RRA788-1.html https://www.rand.org/pubs/research_reports/RRA788-1.html:
“Although the ratio of U.S. to other-country prices varied depending on the comparison country and insulin category, U.S. prices were always higher (often five to ten times higher) than those in other countries.“
“Other countries” includes Canada and Germany, so they didn’t look at particularly poor countries. The linked PDF says
“The average U.S. manufacturer price per standard unit across all insulins was $98.70, compared with $6.94 in Australia, $12.00 in Canada, $7.52 in the United Kingdom, and $8.81 across all non-U.S. OECD countries combined”
- jellicle 5y agoAll of those countries set how much they'll pay for insulin. They have price controls. The USA does the opposite; requires governmental medical insurance providers NOT to bargain with pharma companies and instead explicitly requires them to pay whatever price the pharma company sets. Low prices could come from either a) a robust, competitive market in producing and selling insulin or b) governmental price controls. The USA explicitly chooses not to have either. Other countries typically choose b) backed up by a threat of a) (if you're a pain in the ass over our negotiated price controls, we'll go source a large supply of insulin from somewhere else).
- boublepop 5y ago> The USA does the opposite; requires governmental medical insurance providers NOT to bargain with pharma companies and instead explicitly requires them to pay whatever price the pharma company sets. That’s either a gross misunderstanding or deliberate misinformation. There is both price negotiations and significant rebates negotiated by pharmacy benefits managers who will often make 75% of the profit on the sale of the drugs back as rebates. They then distribute that back to insurers and other parties. Sadly those enormous rebates don’t seem to reach or benefit the patients.
- jellicle 5y ago> > requires governmental medical insurance providers
- RHSeeger 5y agoAdd to that that the insulins used by a lot of people are over 20 years old and off patent. However, they are biologics and, as such, can't be simply made as a generic. Any "generic" needs to go through testing and approval, which means the generics (like Basaglar is for Lantus) aren't that much cheaper (80% of the cost, I believe).